Pygeum

Metadata

Approved Indications

Commission E (Germany)

• Not formally monographed by Commission E (pygeum was more of a French than German tradition)

ESCOP

• Published monograph (2020): Symptomatic treatment of micturition disorders in BPH
  • Dysuria
  • Pollakisuria (frequency)
  • Nocturia
  • Urine retention
  • Stages I, II, and III (Alken and Vahlensieck classifications)
• Notably, ESCOP includes stage III — broader than most saw palmetto recommendations

EMA/HMPC

• EMA has conducted assessment of Prunus africana cortex
• Assessment report published evaluating safety and efficacy
• Classified for traditional use
• The EMA assessment concluded that “Pygeum extract is deemed non-toxic and suitable for long-term use for humans”

Agreement/Disagreement

• ESCOP: Positive, with broad indication covering BPH stages I-III
• EMA: Assessment report available; traditional use framework
• No Commission E monograph: Reflecting pygeum’s French rather than German origin in European phytotherapy
• France: Tadenan is a licensed pharmaceutical product; historically the primary European market
• US: Dietary supplement; Cochrane review acknowledged but not integrated into AUA guidelines
• Cochrane review: Positive, showing modest efficacy — this is the strongest independent evidence base

Conditions Treated

• Benign prostatic hyperplasia (BPH) — symptomatic treatment of:
  • Nocturia
  • Pollakisuria (frequency)
  • Dysuria
  • Urinary retention
  • Weak urinary stream
• Stages I-III (ESCOP) — notably including more advanced BPH than typically indicated for saw palmetto or nettle root

Mechanism of Action

Primary Mechanisms

1. Anti-Androgenic Activity

   • Inhibition of androgen and progesterone receptors in prostate tissue
   • Reduces androgen-driven prostate cell proliferation
   • Beta-sitosterol and other phytosterols compete with endogenous androgens

2. Anti-inflammatory (5-Lipoxygenase Inhibition)

   • Inhibition of 5-lipoxygenase (5-LOX) pathway
   • Reduces leukotriene production in prostate tissue
   • This anti-inflammatory mechanism distinguishes pygeum from saw palmetto’s primarily COX-pathway inhibition

3. Anti-proliferative Effects

   • Inhibition of prostate cell proliferation
   • Induction of apoptosis in stromal cells
   • May directly reduce prostatic growth

4. Bladder Protection (Detrusor Effects)

   • Histamine-mediated protective response to the detrusor muscle
   • May improve bladder contractility and reduce irritative symptoms
   • This mechanism is unique among BPH phytotherapeutics

5. Reduction of Prostatic Edema

   • Anti-edematous effect on prostatic tissue
   • May contribute to improved urinary flow independent of prostate size reduction

Key Bioactive Compounds

• Phytosterols: Beta-sitosterol (key compound; also studied as standalone BPH treatment), campesterol, stigmasterol
• Pentacyclic triterpenes: Ursolic acid, oleanolic acid — anti-inflammatory
• Ferulic acid esters: N-docosanol, tetracosanol — anti-edematous
• Fatty acids: Linoleic acid, palmitic acid, oleic acid
• N-butylbenzenesulfonamide [UNCERTAIN — reported as a constituent but may be a contaminant]

Clinical Evidence Summary

Cochrane Review (Wilt et al., 2002)

• Scope: 18 RCTs involving 1,562 men
• Results:
  • Pygeum significantly improved BPH symptoms (p<0.001 to p<0.05)
  • Self-rated improvement: Men using pygeum were more than twice as likely to report improvement (RR = 2.1)
  • Nocturia: Reduced by 19%
  • Residual urine volume: Reduced by 24%
  • Peak urine flow: Increased by 23%
• Adverse effects: Mild and comparable to placebo; GI discomfort most common
• Limitations: Many trials were small, short-duration, and used varied outcome measures. Most predated IPSS standardization
• [Source: Cochrane Database Syst Rev, 2002]

Meta-analysis (Ishani et al., 2000, Am J Med)

• Systematic review and quantitative meta-analysis
• Confirmed modest but significant improvement in urological symptoms and flow measures
• Total of 1,310 patients analyzed

Key Individual Trials

Tadenan Multicenter Trial

• Sample size: n=263
• Intervention: Tadenan 100 mg daily
• Result: Significant improvement in BPH symptoms

Tadenan 50mg vs 100mg

• Design: Multicenter trial comparing dosing regimens
• Finding: Both 50mg twice daily and 100mg once daily were effective
• Implication: Once-daily dosing is viable

Comparison with Other BPH Herbs

• Pygeum evidence is considered stronger than nettle root or pumpkin seed but weaker than hexane-extract saw palmetto
• Different mechanism profile (5-LOX emphasis) suggests potential for combination therapy
• Less studied than saw palmetto in head-to-head trials

European vs US/Anglophone Consensus

Safety Profile

Contraindications

• Known hypersensitivity to Prunus africana or Rosaceae family
• No other specific contraindications identified
• Suitable for long-term use per EMA assessment

Drug Interactions

• Finasteride/Dutasteride: Theoretical additive anti-androgenic effect; clinical significance unknown
• Anticoagulants: No specific interaction documented
• No significant drug interactions formally identified
• Considered to have a very favorable drug-interaction profile

Side Effects

• Mild and infrequent: GI discomfort (nausea, abdominal pain, diarrhea, constipation)
• Frequency: Comparable to placebo in clinical trials
• No serious adverse effects reported in the Cochrane review
• Overall: Excellent safety and tolerability profile

Pregnancy/Lactation

• Not applicable (BPH is a male condition)
• No data on use in women; theoretical anti-androgenic effects would warrant avoidance in women of childbearing potential

Clinical Dosage

Standardized Dosage Forms

Key Standardized Products

• Tadenan (Solvay/Fournier, France): The reference product; 50mg and 100mg capsules
  • Lipophilic extract standardized to contain 14% triterpenes including beta-sitosterol
  • n-hexane/dichloromethane extraction
• Pygenil (Indena, Italy): Standardized extract
• Various US supplement brands (variable quality/standardization)

Duration of Treatment

• Clinical trials used 1-4 month treatment periods
• ESCOP supports longer-term use for ongoing BPH management
• Minimum 6-8 weeks for initial assessment of effect
• EMA deems it suitable for long-term use

Sustainability and Conservation Concerns

CITES Status

• CITES Appendix II since 1995
• International trade requires export permits from country of origin
• All commercial imports must comply with CITES regulations

Conservation Status

• IUCN Red List: Classified as Vulnerable
• Populations declining in many African montane forest habitats

Harvesting Concerns

• Bark stripping: The primary method of harvest; sustained girdling (ring-barking) often kills trees
• Maturation time: Trees need 15+ years to reach harvestable size
• Annual harvest: Over 3,300 tonnes of bark harvested annually in the late 1990s
• Geographic source: Primarily Cameroon, Madagascar, Kenya, Democratic Republic of Congo
• Historical shift: From subsistence use to large-scale international commercial trade over 40 years

Conservation Actions

• Over 1,610,000 P. africana trees planted in Cameroon (1976-2007)
• Efforts to develop separate, traceable supply chains from cultivated stocks
• Some manufacturers (e.g., Natures Best, UK) have voluntarily stopped selling pygeum due to sustainability concerns
• US Fish & Wildlife Service has issued guidance letters to importers/exporters regarding CITES compliance

Ethical Consideration for Practitioners

• The sustainability issue is a legitimate clinical consideration when choosing among BPH phytotherapeutics
• Saw palmetto (cultivated/wild-harvested in Florida, abundant), nettle root (cultivated, abundant), and pumpkin seed (agricultural crop) do not carry comparable sustainability concerns
• Practitioners should be aware of the conservation dimension and may wish to preferentially recommend sustainable alternatives when clinically appropriate

Sources

• Cochrane Review — Pygeum africanum for BPH (PMC)
• Cochrane Review — Pygeum africanum (PubMed)
• ESCOP Monograph 2020 — Pruni africanae cortex
• EMA Assessment Report on Prunus africana cortex
• Ishani et al. 2000 — Meta-analysis (Am J Med)
• Anti-Inflammatory Potential of Pygeum (PMC)
• CITES — Prunus africana Documentation
• Prunus africana Overexploitation (PMC)
• IUCN Red List — Prunus africana
• US Fish & Wildlife Service — CITES Pygeum Notice
• Natures Best — Why We Don’t Sell Pygeum

Connections

• See Saw Palmetto for the most widely studied BPH herb alternative
• See Nettle Root and Pumpkin Seed for sustainable BPH herb alternatives